These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 26608935)

  • 1. Assessment of in vitro metabolic stability, plasma protein binding, and pharmacokinetics of E- and Z-guggulsterone in rat.
    Chhonker YS; Chandasana H; Mukkavilli R; Prasad YD; Laxman TS; Vangala S; Bhatta RS
    Drug Test Anal; 2016 Sep; 8(9):966-75. PubMed ID: 26608935
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-vitro metabolism, CYP profiling and metabolite identification of E- and Z- guggulsterone, a potent hypolipidmic agent.
    Chhonker YS; Chandasana H; Bala V; Mukkavilli R; Kumar D; Vangala S; Bhatta RS
    J Pharm Biomed Anal; 2018 Oct; 160():202-211. PubMed ID: 30099292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A4 mediated pharmacokinetics drug interaction potential of Maha-Yogaraj Gugglu and E, Z guggulsterone.
    Sabarathinam S; Rajappan Chandra SK; Thangavel Mahalingam V
    Sci Rep; 2021 Jan; 11(1):715. PubMed ID: 33436877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of P-glycoprotein efflux activity by Z-guggulsterone of Commiphora mukul at the blood-brain barrier.
    Xu HB; Yu J; Xu LZ; Fu J
    J Neurol Sci; 2016 Apr; 363():147-52. PubMed ID: 27000241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of oral pharmacokinetics, in vitro metabolism, blood partitioning and plasma protein binding of novel antidiabetic agent, S009-0629 in rats.
    Valicherla GR; Italiya KS; Gupta CP; Mishra S; Riyazuddin M; Syed AA; Singh SK; Shahi S; Taneja G; Wahajuddin M; Goel A; Gayen JR
    Drug Dev Res; 2018 Jun; 79(4):173-183. PubMed ID: 29989222
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Elucidation of pharmacokinetics of novel DNA ligase I inhibitor, S012-1332 in rats: Integration of in vitro and in vivo findings.
    Riyazuddin M; Valicherla GR; Husain A; Hussain MK; Shukla M; Katekar R; Gupta AP; Singh P; Banerjee D; Hajela K; Gayen JR
    J Pharm Biomed Anal; 2019 Jan; 162():205-214. PubMed ID: 30265980
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HPTLC method for guggulsterone. I. Quantitative determination of E- and Z-guggulsterone in herbal extract and pharmaceutical dosage form.
    Agrawal H; Kaul N; Paradkar AR; Mahadik KR
    J Pharm Biomed Anal; 2004 Sep; 36(1):33-41. PubMed ID: 15351045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic characterization of a natural product-inspired novel MEK1 inhibitor E6201 in preclinical species.
    Kumar V; Schuck EL; Pelletier RD; Farah N; Condon KB; Ye M; Rowbottom C; King BM; Zhang ZY; Saxton PL; Wong YN
    Cancer Chemother Pharmacol; 2012 Jan; 69(1):229-37. PubMed ID: 21698359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Simultaneous estimation of E- and Z-isomers of guggulsterone in rabbit plasma using liquid chromatography tandem mass spectrometry and its application to pharmacokinetic study.
    Bhatta RS; Kumar D; Chhonker YS; Jain GK
    Biomed Chromatogr; 2011 Sep; 25(9):1054-60. PubMed ID: 21268049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
    Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
    Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical comprehensive physicochemical and pharmacokinetic profiling of novel nitroimidazole derivative IIIM-019 - A potential oral treatment for tuberculosis.
    Kour G; Kumar A; Singh PP; Sharma S; Bhagat A; Vishwakarma RA; Ahmed Z
    Pulm Pharmacol Ther; 2016 Oct; 40():44-51. PubMed ID: 27457685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preclinical pharmacokinetics and ADME characterization of a novel anticancer chalcone, cardamonin.
    Jaiswal S; Shukla M; Sharma A; Rangaraj N; Vaghasiya K; Malik MY; Lal J
    Drug Test Anal; 2017 Aug; 9(8):1124-1136. PubMed ID: 27794181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, plasma protein binding, and metabolism of a potential natural chemosensitizer from Marsdenia tenacissima in rats.
    Xie B; Jiang SQ; Shen XL; Wu HQ; Hu YJ
    J Ethnopharmacol; 2021 Dec; 281():114544. PubMed ID: 34419608
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical pharmacokinetics and metabolism of BMS-214778, a novel melatonin receptor agonist.
    Vachharajani NN; Yeleswaram K; Boulton DW
    J Pharm Sci; 2003 Apr; 92(4):760-72. PubMed ID: 12661062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical pharmacokinetics and in vitro metabolism of dasatinib (BMS-354825): a potent oral multi-targeted kinase inhibitor against SRC and BCR-ABL.
    Kamath AV; Wang J; Lee FY; Marathe PH
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):365-76. PubMed ID: 17429625
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics and metabolism of a RAS farnesyl transferase inhibitor in rats and dogs: in vitro-in vivo correlation.
    Singh R; Chen IW; Jin L; Silva MV; Arison BH; Lin JH; Wong BK
    Drug Metab Dispos; 2001 Dec; 29(12):1578-87. PubMed ID: 11717177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of Pharmacokinetics and Metabolism Profiles of SCH 58261 in Rats Using Liquid Chromatography-Mass Spectrometric Method.
    Park Y; Park MH; Byeon JJ; Shin SH; Lee BI; Choi JM; Kim N; Park SJ; Park MJ; Lim JH; Shin YG
    Molecules; 2020 May; 25(9):. PubMed ID: 32397307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Simultaneous determination of imperatorin and its metabolites in vitro and in vivo by a GC-MS method: application to a bioavailability and protein binding ability study in rat plasma.
    Zhao G; Peng C; Du W; Wang S
    Biomed Chromatogr; 2014 Jul; 28(7):947-56. PubMed ID: 24357077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Zhou S; Kestell P; Tingle MD; Paxton JW
    Cancer Chemother Pharmacol; 2002 Feb; 49(2):126-32. PubMed ID: 11862426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In Vitro Metabolic Stability and Permeability of Gymnemagenin and Its In Vivo Pharmacokinetic Correlation in Rats - A Pilot Study.
    Bera R; Kundu A; Sen T; Adhikari D; Karmakar S
    Planta Med; 2016 Apr; 82(6):544-50. PubMed ID: 26916641
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.